Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1998-03-26
1999-05-11
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K31/135
Patent
active
059028300
ABSTRACT:
Use of droloxifene in the treatment of cardiovascular diseases.
REFERENCES:
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5254594 (1993-10-01), Niikura et al.
patent: 5384332 (1995-01-01), Fontana
patent: 5426123 (1995-06-01), Fontana
patent: 5455275 (1995-10-01), Fontana
Gill-Sharma, M.K., et al., "Effects of Tamoxifen on the Fertility of Male Rats", Journal of Reproduction and Fertility 99, 395-402 (1993).
Schneider, M. R. et al., "Effect of zindoxifens on experimental prostatic tumours of the rat", J Cancer Res Clin Oncol 117:33-36 (1991).
Faulkner, et al., "Regional and Total Body Bone Mineral Content, Bone Mineral Density, and Total Body Tissue Composition in Children 8-16 Years of Age" Calcified tissue 53:7-12 (1993).
Jones, Robert C., "The Effect of a Luteininzing Hormone Releasing Hormone (LRH) Agonist (Wy-40,972), Levonorgestrel, Danazol and Ovariectomy on Experimental Endometriosis in the Rat" Acta Endocrinologica 106, 282-8 (1994).
Wiseman, H., "Tamoxifen: New Membrane-Mediated Mechanisms of Action and Therapeutic Advances", Tips, 101-15 (1994).
Wiseman, H., et al., "Droloxifene (3-hydroxytamoxifen) has membrane antioxidant ability: potential relevance to its mechanism of therapeutic action in breast cancer", Cancer Letters, 66 61-68 (1992).
Steinberg, D., et al., "Beyond Cholesterol Modifications of Low-Density Lipoprotein that increase its Atherogenicity", The New England Journal of Medicine, 915-924 (1989).
Wiseman, H., et al., Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen?, Biochem, J. 292 635 (1993).
Pritchard, K., "Summary", Am. J. Clin. Oncol., 14 (Suppl. 2) S62-S63 (1991).
Cypriani, B., et al. "Role of Estrogen Receptors and Antiestrogen Binding Sites in an Early Effects of Antiestrogens, the Inhibition of Cholesterol Biosynthesis", J. Steriod Biochem., vol. 31, No. 5, 763-771, (1988).
Bruning, P.F., "Droloxifene, A New Anti-estrogen in Postmenopausal Advanced Breast Cancer: Preliminary Results of a Double-blind Dose-finding Phase II Trial", Eur F Cancer, vol. 28A, No. 8/9, 1404-1407 (1992).
Neubauer, B. L., et al., "Endocrine and Antiprostatic Effects of Raloxifene (LY156758) in Male Rats", The Prostate, 23:245-262 (1993).
Wiseman, H., et al., "Tamoxifene Inhibits Lipids Peroxidation in Cardiac Microsomes", Biochemical Pharmacology, vol. 45, No. 9, 1851-1855 (1993).
Love, R. R., "Effects of Tamoxifen on Cardiovascular Risk Factor in Postmenopausal Women", Annals of Internal Medicine, 115, 860-864 (1991).
Schwartz, J. et al., "Clinical Pharmacology of Estrogens: Cardiovascular Actions and Cardioprotective Benefits of Replacement Therapy in Postmenopausal Women", J. Clin. Pharmacol, 35:314-329 (1995).
Di Silverio, F., et al., "Pharmacological combinations in the treatment of benign prostatic hypertrophy", Journal d'Urologie, No. 6, 316-320 (1993).
Bierman, E.L., "Atherosclerosis and other forms of arteriosclerosis", 1106-1110 (1989).
"Raloxifene Hydrochloride EN=090328", Drugs of the Future, vol. 15(7), 762-63 (1990).
Loser Roland
Schliack Michael
Thompson David D.
Benson Gregg C.
Brokke Mervin E.
Goldberg Jerome D.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Use of droloxifene for the treatment of cardiovascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of droloxifene for the treatment of cardiovascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of droloxifene for the treatment of cardiovascular disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-245874